A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Conditions: Carcinoma Interventions: Biological: Dostarlimab; Drug: Carboplatin; Drug: Paclitaxel Sponsors: GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Endometrial Cancer | Japan Health | Research | Study